Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. more
Time Frame | VKTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -13.33% | -3.35% | -2.97% |
1-Month Return | -19.45% | -3.49% | -0.66% |
3-Month Return | -39.13% | -12.6% | 2.71% |
6-Month Return | -17.73% | -6.91% | 7.21% |
1-Year Return | 116.66% | 1.19% | 23.04% |
3-Year Return | 738.18% | -0.21% | 28.43% |
5-Year Return | 419.27% | 33.09% | 82.88% |
10-Year Return | 363.06% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 10.73K | 10.70K | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.72,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 260.00K | 277.00K | 296.00K | 291.00K | 292.00K | [{"date":"2019-12-31","value":87.84,"profit":true},{"date":"2020-12-31","value":93.58,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.31,"profit":true},{"date":"2023-12-31","value":98.65,"profit":true}] |
Gross Profit | (260.00K) | 10.73K | (296.00K) | (291.00K) | (292.00K) | [{"date":"2019-12-31","value":-2422.89,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-2758.36,"profit":false},{"date":"2022-12-31","value":-2711.77,"profit":false},{"date":"2023-12-31","value":-2721.09,"profit":false}] |
Gross Margin | - | 100.00% | (2766.10%) | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-2766.1,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 32.69M | 42.66M | 55.68M | 70.36M | 100.83M | [{"date":"2019-12-31","value":32.42,"profit":true},{"date":"2020-12-31","value":42.31,"profit":true},{"date":"2021-12-31","value":55.23,"profit":true},{"date":"2022-12-31","value":69.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (32.69M) | (42.66M) | (55.68M) | (70.36M) | (100.83M) | [{"date":"2019-12-31","value":-3268700000,"profit":false},{"date":"2020-12-31","value":-4266200000,"profit":false},{"date":"2021-12-31","value":-5568200000,"profit":false},{"date":"2022-12-31","value":-7035500000,"profit":false},{"date":"2023-12-31","value":-10082700000,"profit":false}] |
Total Non-Operating Income/Expense | 13.81M | 45.75M | 1.38M | 3.02M | 25.91M | [{"date":"2019-12-31","value":30.19,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":3.01,"profit":true},{"date":"2022-12-31","value":6.6,"profit":true},{"date":"2023-12-31","value":56.63,"profit":true}] |
Pre-Tax Income | (25.78M) | (39.49M) | (54.99M) | (68.87M) | (85.89M) | [{"date":"2019-12-31","value":-2577900000,"profit":false},{"date":"2020-12-31","value":-3949500000,"profit":false},{"date":"2021-12-31","value":-5499000000,"profit":false},{"date":"2022-12-31","value":-6886700000,"profit":false},{"date":"2023-12-31","value":-8589500000,"profit":false}] |
Income Taxes | (4.00K) | (3.48M) | (988.00K) | (1.49M) | (292.00K) | [{"date":"2019-12-31","value":-400000,"profit":false},{"date":"2020-12-31","value":-348400000,"profit":false},{"date":"2021-12-31","value":-98800000,"profit":false},{"date":"2022-12-31","value":-148800000,"profit":false},{"date":"2023-12-31","value":-29200000,"profit":false}] |
Income After Taxes | (25.77M) | (36.01M) | (54.00M) | (67.38M) | (85.60M) | [{"date":"2019-12-31","value":-2577500000,"profit":false},{"date":"2020-12-31","value":-3601100000,"profit":false},{"date":"2021-12-31","value":-5400200000,"profit":false},{"date":"2022-12-31","value":-6737900000,"profit":false},{"date":"2023-12-31","value":-8560300000,"profit":false}] |
Income From Continuous Operations | (25.78M) | (39.49M) | (54.99M) | (69.13M) | (80.85M) | [{"date":"2019-12-31","value":-2577900000,"profit":false},{"date":"2020-12-31","value":-3949500000,"profit":false},{"date":"2021-12-31","value":-5499000000,"profit":false},{"date":"2022-12-31","value":-6912500000,"profit":false},{"date":"2023-12-31","value":-8084900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (25.78M) | (39.49M) | (54.00M) | (67.38M) | (85.89M) | [{"date":"2019-12-31","value":-2577900000,"profit":false},{"date":"2020-12-31","value":-3949500000,"profit":false},{"date":"2021-12-31","value":-5400200000,"profit":false},{"date":"2022-12-31","value":-6737900000,"profit":false},{"date":"2023-12-31","value":-8589500000,"profit":false}] |
EPS (Diluted) | (0.36) | (0.54) | (0.72) | (0.91) | (0.92) | [{"date":"2019-12-31","value":-36,"profit":false},{"date":"2020-12-31","value":-54,"profit":false},{"date":"2021-12-31","value":-72,"profit":false},{"date":"2022-12-31","value":-91,"profit":false},{"date":"2023-12-31","value":-92,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VKTX | |
---|---|
Cash Ratio | 36.23 |
Current Ratio | 36.47 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VKTX | |
---|---|
ROA (LTM) | -12.68% |
ROE (LTM) | -15.50% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VKTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.03 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.97 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VKTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 5.71 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
PEG | NM |
Viking Therapeutics Inc (VKTX) share price today is $41.49
Yes, Indians can buy shares of Viking Therapeutics Inc (VKTX) on Vested. To buy Viking Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VKTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Viking Therapeutics Inc (VKTX) via the Vested app. You can start investing in Viking Therapeutics Inc (VKTX) with a minimum investment of $1.
You can invest in shares of Viking Therapeutics Inc (VKTX) via Vested in three simple steps:
The 52-week high price of Viking Therapeutics Inc (VKTX) is $99.41. The 52-week low price of Viking Therapeutics Inc (VKTX) is $17.23.
The price-to-earnings (P/E) ratio of Viking Therapeutics Inc (VKTX) is
The price-to-book (P/B) ratio of Viking Therapeutics Inc (VKTX) is 5.71
The dividend yield of Viking Therapeutics Inc (VKTX) is 0.00%
The market capitalization of Viking Therapeutics Inc (VKTX) is $5.20B
The stock symbol (or ticker) of Viking Therapeutics Inc is VKTX